Casey v. Merck & Co., Inc.

CourtSupreme Court of Virginia
DecidedMarch 2, 2012
Docket111438
StatusPublished

This text of Casey v. Merck & Co., Inc. (Casey v. Merck & Co., Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Casey v. Merck & Co., Inc., (Va. 2012).

Opinion

Present: All the Justices

JOHN CASEY, INDIVIDUALLY AND AS ADMINISTRATOR OF THE ESTATE OF ORA CASEY, ET AL. OPINION BY v. Record No. 111438 JUSTICE S. BERNARD GOODWYN March 2, 2012 MERCK & CO., INC.

UPON QUESTIONS OF LAW CERTIFIED BY THE UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT

Pursuant to Article VI, Section 1 of the Constitution of

Virginia and our Rule 5:40, we accepted the following certified

questions from the United States Court of Appeals for the

Second Circuit:

(1) Does Virginia law permit equitable tolling of a state statute of limitations due to the pendency of a putative class action in another jurisdiction?

(2) Does Va. Code Ann. § 8.01-229(E)(1) permit tolling of a state statute of limitations due to the pendency of a putative class action in another jurisdiction?

Background

On September 15, 2005, a putative class action, Wolfe v.

Merck & Co., was filed in the United States District Court for

the Middle District of Tennessee. The putative class included

"[a]ll persons who consume or have consumed FOSAMAX, whether

intravenously or by mouth." The representative plaintiffs in

the class action asserted claims of strict liability,

negligence and medical monitoring against Merck & Co., Inc.

(Merck). The Wolfe putative class action was transferred to the

United States District Court for the Southern District of New

York by the Judicial Panel on Multidistrict Litigation, which

consolidated certain Fosamax cases. The Southern District of

New York denied class certification and dismissed the Wolfe

class action on January 28, 2008.

Prior to the dismissal of the Wolfe putative class action,

four plaintiffs, all residents of Virginia, filed individual

state law based actions against Merck in the Southern District

of New York, asserting federal diversity jurisdiction. All

four plaintiffs allegedly suffered from osteonecrosis of the

jaw as a result of taking Fosamax. The district court noted

that "[i]t is undisputed that all four plaintiffs filed suit

more than two years after the latest possible date that they

sustained their respective alleged injuries," and that Virginia

law applied to the claims.

Merck moved for summary judgment, alleging that the four

plaintiffs’ actions were untimely under Virginia's two-year

statute of limitations for personal injuries. In response, the

plaintiffs claimed that the Wolfe putative class action, which

was filed within the two-year limitation period, tolled the

running of the Virginia statute of limitations on their

individual actions because they would have been members of the

proposed class had certification been granted. The district

2 court granted Merck's motion, finding that the pendency of the

Wolfe putative class action did not toll Virginia's limitations

period for the four plaintiffs' state law claims.

The plaintiffs appealed to the United States Court of

Appeals for the Second Circuit. The Second Circuit determined

that Virginia law governed whether the Wolfe putative class

action tolled the running of the statute of limitations on the

plaintiffs' individual claims, and asked this Court to

determine whether Virginia law permits equitable or statutory

tolling of a Virginia statute of limitations due to the

pendency of a putative class action in another jurisdiction.

Facts

The relevant facts, as set forth in the certification

order, are not in dispute. Merck manufactures Fosamax, a

prescription drug that falls within a class of drugs known as

bisphosphonates, which are used to treat bone conditions such

as osteoporosis. Fosamax, a nitrogenous bisphosphonate, has

allegedly been linked to osteonecrosis – bone death – of the

jaw.

The four plaintiffs were prescribed and consumed Fosamax.

Rebecca Quarles was diagnosed with osteonecrosis of the jaw and

failure of dental implants in 2003 and sued Merck in 2007.

Dorothy Deloriea was prescribed and took Fosamax in 1999,

developed osteomyelitis and osteonecrosis of the jaw in 2004,

3 and filed her complaint against Merck in 2008. Ora Casey began

taking Fosamax in 2000 and was diagnosed with osteonecrosis of

the jaw in 2004. She died in 2007 and her estate initiated

this action in 2008. Roberta Brodin was prescribed and took

Fosamax in 2001 and was diagnosed with osteonecrosis of the jaw

in 2005. She initiated her action in 2007.

The plaintiffs' complaints against Merck assert

exclusively Virginia state law claims: strict liability,

failure to warn, breach of express and implied warranty, and

negligence in the design, testing, development, manufacture,

labeling, marketing, distribution and sale of Fosamax. As a

result, it is agreed that Virginia law governs the question of

whether the filing of the putative class tolled the running of

the statute of limitations on their claims.

Analysis

The two certified questions of law relate to Virginia's

statute of limitations for personal injury actions. ∗ "[T]he

applicability of the statute of limitations is a purely legal

question of statutory construction." Conger v. Barrett, 280

Va. 627, 630, 702 S.E.2d 117, 118 (2010).

∗ Code § 8.01-243(A) provides: "every action for personal injuries, whatever the theory of recovery . . . shall be brought within two years after the cause of action accrues."

4 The plaintiffs contend that Virginia law permits equitable

tolling of a Virginia statute of limitations based upon the

filing of a cross-jurisdictional putative class action.

Plaintiffs also argue that the pendency of a putative class

action in another jurisdiction statutorily tolls Virginia's

statute of limitations under Code § 8.01-229(E)(1). Merck

responds that Virginia law does not permit equitable tolling of

a statute of limitations, and that Code § 8.01-229(E)(1) does

not provide for tolling due to the pendency of a putative class

action in another jurisdiction.

Certified Question (1)

It is well-established that "statutes of limitations are

strictly enforced and must be applied unless the General

Assembly has clearly created an exception to their

application." Rivera v. Witt, 257 Va. 280, 283, 512 S.E.2d

558, 559 (1999). A statute of limitations may not be tolled,

"or an exception applied, in the absence of a clear statutory

enactment to such effect." Arrington v. Peoples Sec. Life Ins.

Co., 250 Va. 52, 55-56, 458 S.E.2d 289, 291 (1995). "[A]ny

doubt must be resolved in favor of the enforcement of the

statute." Id. at 55, 458 S.E.2d at 290-91.

Given these principles, there is no authority in Virginia

jurisprudence for the equitable tolling of a statute of

limitations based upon the pendency of a putative class action

5 in another jurisdiction. Certified Question (1) is answered in

the negative.

Certified Question (2)

Code § 8.01-229(E)(1) provides that "if any action is

commenced within the prescribed limitation period and for any

cause abates or is dismissed without determining the merits,

the time such action is pending shall not be computed as part

Free access — add to your briefcase to read the full text and ask questions with AI

Related

American Pipe & Construction Co. v. Utah
414 U.S. 538 (Supreme Court, 1974)
Conger v. Barrett
702 S.E.2d 117 (Supreme Court of Virginia, 2010)
Harmon v. Sadjadi
639 S.E.2d 294 (Supreme Court of Virginia, 2007)
Braddock v. BD. OF SUP'RS OF LOUDOUN
601 S.E.2d 552 (Supreme Court of Virginia, 2004)
Brake v. Payne
597 S.E.2d 59 (Supreme Court of Virginia, 2004)
Fowler v. Winchester Medical Center, Inc.
580 S.E.2d 816 (Supreme Court of Virginia, 2003)
Welding, Inc. v. Bland County Service Authority
541 S.E.2d 909 (Supreme Court of Virginia, 2001)
Rivera v. Witt
512 S.E.2d 558 (Supreme Court of Virginia, 1999)
W. S. Carnes, Inc. v. Board of Supervisors
478 S.E.2d 295 (Supreme Court of Virginia, 1996)
Arrington v. Peoples Security Life Insurance
458 S.E.2d 289 (Supreme Court of Virginia, 1995)
McDaniel v. North Carolina Pulp Co.
95 S.E.2d 201 (Supreme Court of Virginia, 1956)
Harbour Gate Owners' Ass'n v. Berg
348 S.E.2d 252 (Supreme Court of Virginia, 1986)

Cite This Page — Counsel Stack

Bluebook (online)
Casey v. Merck & Co., Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/casey-v-merck-co-inc-va-2012.